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Abstract
Background: Cardiovascular disease is the leading cause of death in Brazil, and hypertension is its major risk factor.
The benefit of its drug treatment to prevent major cardiovascular events was consistently demonstrated.
Angiotensin-receptor blockers (ARB) have been the preferential drugs in the management of hypertension
worldwide, despite the absence of any consistent evidence of advantage over older agents, and the concern that
they may be associated with lower renal protection and risk for cancer. Diuretics are as efficacious as other agents,
are well tolerated, have longer duration of action and low cost, but have been scarcely compared with ARBs.
A study comparing diuretic and ARB is therefore warranted.
Methods/design: This is a randomized, double-blind, clinical trial, comparing the association of chlorthalidone and
amiloride with losartan as first drug option in patients aged 30 to 70 years, with stage I hypertension. The primary
outcomes will be variation of blood pressure by time, adverse events and development or worsening of
microalbuminuria and of left ventricular hypertrophy in the EKG. The secondary outcomes will be fatal or non-fatal
cardiovascular events: myocardial infarction, stroke, heart failure, evidence of new subclinical atherosclerosis and
sudden death. The study will last 18 months. The sample size will be of 1200 participants for group in order to
confer enough power to test for all primary outcomes. The project was approved by the Ethics committee of each
participating institution.
Discussion: The putative pleiotropic effects of ARB agents, particularly renal protection, have been disputed, and
they have been scarcely compared with diuretics in large clinical trials, despite that they have been at least as
efficacious as newer agents in managing hypertension. Even if the null hypothesis is not rejected, the information
will be useful for health care policy to treat hypertension in Brazil.
Clinical trials registration number: ClinicalTrials.gov: NCT00971165
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Background
Cardiovascular disease (CVD) is the leading cause of
death in Brazil, and high blood pressure is its major
risk. factor. The prevalence of hypertension in Brazil is
within 22.3 to 44% of adults [1]. The benefit of drug
treatment of hypertension to prevent major cardiovascu-
lar events was consistently demonstrated in a large ser-
ies of clinical trials controlled by placebo. The
superiority of any particular agent among the groups of
blood pressure-lowering drugs was investigated in var-
ious clinical trials. ALLHAT, the largest and better
designed trial, showed that chlorthalidone had similar
efficacy to prevent fatal and non-fatal coronary events as
an ACE inhibitor (lisinopril) and a calcium channel
blocker agent (amlodipine) [2]. Chlorthalidone was
superior to lisinopril in the prevention of other cardio-
vascular outcomes, particularly of stroke in black partici-
pants, and it was superior to amlodipine in the
prevention of heart failure. In the VALUE trial, amlodi-
pine was superior to valsartan, an angiotensin-receptor
blocker (ARB) agent, in the prevention of CHD and
stroke [3]. The most recent and extensive meta-analysis
of trials that compared the efficacy of blood pressure-
lowering drugs against placebo and against each other
failed to demonstrated substantial advantage of any
group of agents [4]. Nonetheless, ARBs have been pre-
ferential drugs in the management of hypertension,
being five out of the ten agents more frequently pre-
scribed in the USA in 2007 [5].
Data from some trials have shed some concern about
the safety of ARB agents [6], but these findings require
corroboration in other studies. The main concern is
with the guidelines’ supported preference for ARB
agents to prevent renal damage, particularly in patients
with diabetes. Most data supporting such preference
came from placebo controlled trials, not controlling for
their blood pressure-lowering effect. These agents did
not show any superiority over angiotensin converting
enzyme (ACE) inhibitors to prevent renal outcomes, and
the association of these agents was clearly deleterious in
the ONTARGET trial [7]. It is of note that even the
beneficial effects of ACE inhibitors in this context were
mostly demonstrated in studies not controlled by other
blood pressure agents. In the only study that compared
an ACE inhibitor with a diuretic, the incidence of
microalbuminuria was similar [8]. In the ALLHAT trial,
the incidence of end-stage renal disease was about 70%
higher in patients with diabetes and with glomerular fil-
tration rate between 60 and 80 ml/min, randomized to
lisinopril and anlodipine, instead of chlorthalidone [9].
A complex clinical trial investigated the efficacy of an
ARB agent and of an ACE inhibitor to prevent renal
damage in patients with type I diabetes [10]. Change in
mesangial fractional volume per glomerulus over the
5-year period of follow-up, the primary outcome, did
not differ significantly between the placebo and treat-
ment groups. Moreover, the 5-year cumulative incidence
of microalbuminuria was 17% with losartan versus 6%
with placebo and 4% with enalapril (P = 0.01).
There is no head-to-head comparison between diure-
tics and ARB agents in the prevention of hard cardiovas-
cular outcomes, and even the comparison of their blood
pressure-lowering effects was scarcely reported. Despite
this, ARB agents are the leading brands in terms of
profits in various countries in the world, including Bra-
zil. This leadership seems to be based on a strong com-
mercial strategy, which may have introduced bias in the
evidences of clinical trials in favor of these drugs
[11,12]. The idea that they have blood pressure-indepen-
dent effects is accepted by most, despite the evidences of
better designed trials and of the powerful meta-analysis
of Law, Morris and Wald [4]. The option of an ARB
agent, instead of a diuretic, as the first line approach in
the public health system in Brazil would result in a large
expenditure of resources, and there is a pressure to
include them in the list of essential drugs provided by
the government.
Diuretics are at least as efficacious as other blood
pressure-lowering drugs, are well tolerated, have longer
duration of action and the advantage of very low cost to
be used in a population intervention [13]. Chlorthali-
done is a more efficacious agent, and should be the pre-
ferential choice of diuretic to be employed in clinical
practice [13]. Its main limitation is to induce hypokale-
mia in some patients, an adverse effect that can be
antagonized by a potassium-sparing diuretic, such as
amiloride [14].
A study comparing diuretic with an ARB agent is
therefore scientifically required. It would be also impor-
tant in Brazil, in order to support the decisions of the
Public Health System in regard to blood pressure drugs
supply for the Brazilian population. Such a study was
demanded and funded by the Health and Technology
Ministries in Brazil.
Trial rationale
ARB agents have good tolerability and putative pleiotro-
pic effects, particularly renal protection, which support
their preference by physicians as an antihypertensive
agent. Independent assessments of the evidence have
questioned these advantages, and a concern with the
safety of these agents, such as the loss of nephroprotec-
tion in patients with diabetes, has emerged. Diuretics,
particularly chlorthalidone, are as efficacious as newer
agents in managing hypertension. Its main adverse
effect, hypokalemia, which is associated with arrhyth-
mias and hyperglycemia, can be circumvented by the
association of potassium-sparing diuretic, such as
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amiloride. Blood pressure has been a valid surrogate of
the beneficial effects of blood pressure-lowering drugs.
In this scenario, the PREVER treatment trial will com-
pare the antihypertensive efficacy of the association of
chlorthalidone plus amiloride with losartan, for the
initial management of hypertension (Clinical trials regis-
tration number: NCT00971165). Other intermediate
outcomes, such as microalbuminuria and left ventricular
hypertrophy, and major cardiovascular outcomes, are
going to be investigated. Even if the null hypothesis is
not rejected (diuretics equivalent to losartan), the infor-
mation will be useful for health care policy to treat
hypertension in Brazil.
Research questions
1. Is losartan more efficacious and safe than the associa-
tion of chlorthalidone with amiloride as the first option
to control blood pressure in patients with stage I
hypertension?
2. Is losartan more efficacious than the association of
chlorthalidone with amiloride as the first option to pre-
vent the development of target-organ damage in patients
with stage I hypertension?
3. Is losartan more efficacious than the association of
chlorthalidone with amiloride as the first option to pre-
vent the occurrence of major cardiovascular events in
patients with stage I hypertension?
Methods
Design
randomized, double-blind, clinical trial, controlled by an
active treatment.
Eligible participants
patients older than 40 years of age with Stage I
hypertension.
Exclusion criteria
low life expectancy, other indications for the use of
diuretics, such as cardiovascular disease, intolerance to
the study drugs, pregnancy.
Random allocation
by a computer generated list, using a validated software
(Random allocator), with variable block sizes and strati-
fied by center.
Interventions
Chlorthalidone plus amiloride up to 25 and 5 mg daily,
versus losartan up to 100 mg daily. Amlodipine up to
10 mg daily and propranolol up to 160 mg/day, in an
open fashion, will be added if blood pressure is not con-
trolled. Figure 1 shows flow-chart of selection of partici-
pants and interventions.
Outcomes
Primary
1. Blood pressure variation and proportion of use of
add-on drugs.
2. Adverse events.
3. Development or worsening of microalbuminuria
and of left ventricular hypertrophy in the EKG.
Secondary
fatal or major cardiovascular events.
Follow-up and duration of the study: outpatient clinical
visits
for evaluation and enrollment and thereafter consulta-
tions at the 3th., 6th., 9th, 12th. and 18th. months. Figure
2 shows the summary of key practical aspects of the
trial.
Assessment of outcomes
Blood pressure will be measured at the follow-up visits
by average blood pressure (two measurements by an
automatic electronic device Microlife BP 3BTO-A,
licensed for fabrication by Micromed Biotecnologia
Ltda, Brasília, Brazil).
Adverse events
adverse events will be investigated by open questions
and by a semi-structured questionnaire including gen-
eral symptoms and the presumed adverse effects of the
drugs used in the trial. Laboratory adverse events, such
as hypokalemia, hyperuricemia and diabetes (glycated
hemoglobin and fasting glucose) will be investigated at
the final visit of the participants
Consent form
Males/ Females, 40 - 70 years old
Offi bl d 140 159/90 99 H
POTENTIALLY ELIGIBLE (Time 0)
ce average oo pressure: - - mm g
If diabetes mellitus: Systolic BP: >130 mmHg
W i ht t l
LIFESTYLE MODIFICATION (Months 1 to 3)
e g con ro
Dash diet like
Low sodium 
Stop smoking
Ph i l ti itys ca ac v y
Consent form
H t i t 1 ( ffi BP)
RANDOMIZATION (Month 3)
yper ens on, s age   o ce 
Blood tests
Urine analysis
ECG
Re-assessment
Office blood pressure
Sid ff t
FOLLOW-UP VISITS (Months 6 to 15) 
e-e ec s
Blood pressure
C t ll d h t i
OUTCOMES (Month 18) 
on ro e  yper ens on
Adverse effects
Diabetes mellitus, microalbuminúria, LHV (ECG), hypokalemia, hyperuricemia
Cardiovascular disease
Figure 1 Flow chart of the PREVER-Treatment trial, describing
the selection, randomization and follow-up process.
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Target-organ damage
Microalbuminuria will be determined by nephelometry.
Left ventricular hypertrophy will be investigated by elec-
trocardiogram, using the Sokolow-Lyon voltage and the
Cornell voltage-duration product.
Cardiovascular outcomes
from a statistical point of view they will be secondary
events, in face of the power of the sample calculated for
the trial. Figure 3 presents the main outcomes that will
be investigated. The cases will be adjudicated on the
basis of interview, hospital charts and exams, death
certificates and verbal autopsy with next-of-kin, by
members of the outcome committee.
Sample size calculation
for non-inferiority, with a P alpha of 0.01, power of 99%,
and SD of 12 mmHg, and maximum acceptable absolute
difference of 4 mmHg (diastolic), it will be necessary to
study 433 patients per group, rounded to 500 patients to
compensate losses. The difference of 5 mmHg (diastolic)
has been achieved, on average, in clinical trials that have
demonstrated the advantage of a drug over placebo or
other drug in the prevention of major cardiovascular out-
comes. In face of the other primary hypotheses of the trial,
and other subprojects that will be undertaken in some
centers, it was decided to study 1200 patients per group.
Statistics
the cumulative incidence of target-organ damage and
adverse events will be analyzed by Chi-square test.
Blood pressure will be compared by ANOVA for multi-
ple measurements and factors, testing for the time-
group interaction. The primary analysis will be by inten-
tion-to-treat. An attempt to measure blood pressure at
the end of trial even for participants that abandoned the
treatment will be undertaken. The rates of controlled
blood pressure by treatment will be evaluated by
Males or females, 40 to 70 years-old, hypertension, stage 1 
at the office blood pressure; no more than 1 antihypertensive,
without allergy to Chlortalidone and Amiloride, no previous 
CHD and severe chronic disease, or pregnant women
Lifestyle
modification
Hypertension
R
Chlortalidone  (12.5 
mg) and Amiloride (2.5 
mg)
Losartan (50 mg)
Doubled dose
+ Amlodipine (5 mg)
3 m
6 m
Doubled dose
+ Amlodipine (5 mg)
+ Amlodipine doubled dose
+ Propranolol (80 mg) 
9 m
12 m
+ Amlodipine doubled dose
+ Propranolol (80 mg) 
Controlled hypertension, Diabetes 
+ Propranolol doubled dose
Controlled hypertension, Diabetes 
15 m + Propranolol doubled dose
mellitus, Microalbuminuria, LHV, 
Hypokalemia, Hyperuricemia, Adverse 
effects, Cardiovascular disease
mellitus, Microalbuminuria, LHV, 
Hypokalemia, Hyperuricemia, Adverse 
effects, Cardiovascular disease
Figure 2 Summary of the PREVER-Treatment trial key practical aspects.
Myocardial infarction
Unstable angina requiring 
hospitalization
Stroke and Ischemic Transitory Attack
Heart failure requiring hospitalization
Peripheral vascular disease requiring 
hospitalization
New subclinical evidence of vascular 
atherosclerotic disease
Sudden death
Figure 3 PREVER-Treatment trial cardiovascular outcomes.
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survival curves and tested by Cox models, censoring the
cases lost in the follow-up. In case of uneven losses by
group, sensitivity analysis will be undertaken.
Logistics
This is a nation-based trial, with 24 clinical centers dis-
tributed in 9 States. A Coordinating Committee is
responsible for the elaboration of this proposal and for
the main decisions of the trial. The study organizational
chart will include an executive Committee, a safety com-
mittee, outcome committee, lab and EKG centers, and
the research units.
Ethical approval
The project and the informed consent form were
approved by the Ethics committee of the Hospital de
Clínicas de Porto Alegre, which is accredited by the
Office of Human Research Protections as an Institu-
tional Review Board, and by the Ethic Committees of
the participating centers. All participants will be asked
to sign the informed consent to participate in the study.
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